Status:
WITHDRAWN
Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Imperial College London
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
35+ years
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a chronic disease characterized by progressive airflow obstruction, chronic cough and dyspnoea in advanced stages. We hope to develop a better understa...
Detailed Description
Techniques such as genomics, proteomics and metabonomics, Technologies that aim to identify and quantify the dynamic set of all small molecules and metabolites present in an organism or a biological s...
Eligibility Criteria
Inclusion
- Inclusion Criteria - Healthy non-smokers
- Non-smoking volunteer aged 40 -75 years (age matched to COPD patients)
- Normal spirometry (FEV1/FVC ratio \>70% and FEV1\>80% predicted)
- Subjects are able to give informed consent Inclusion Criteria-COPD patients (stage 2-3 according to the GOLD guidelines)
- Current and/or ex-smokers with no less than 10 pack-year smoking history aged 40-75 years
- 30% FEV1 \< 80% of predicted (the upper value is a postbronchodilator value)
- FEV1/FVC \< 70%
- Stable COPD (no chest infection requiring antibiotics and/ or oral steroids in the past 2 months)
- Long-acting beta2-agonists and long-acting antimuscarinic bronchodilators need to be stopped at least 8 hours before the study visit
- The subjects are able to give informed consent
- Inclusion Criteria - healthy smokers
- Current smokers aged 40 -75 years (age matched to COPD patients)
- Normal spirometry (normal FEV1/FVC ratio \>70% and FEV1\>80% predicted)
- Subjects are able to give informed consent
- Inclusion Criteria - asthmatics
- Non-smoking asthma patients aged 40 -75 years (age matched to COPD patients)
- Normal spirometry (normal FEV1/FVC ratio \>70% and FEV1\>80% predicted)
- Subjects are able to give informed consent
Exclusion
- Exclusion Criteria - Healthy non-smokers
- Chest infection that required treatment with antibiotics within the last 4 weeks
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
- Any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study Exclusion Criteria-COPD patients
- Bronchodilator reversibility \> 12%
- Chest infection that required treatment with antibiotics within the last 4 weeks
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
- Patients with significant co-morbidities including any psychiatric condition rendering the patient unable to understand the nature, scope and possible consequences of the study as judged by the investigator
- Any other respiratory disease, which is considered by the investigator to be clinically significant
- Exclusion Criteria - healthy smokers
- Chest infection that required treatment with antibiotics within the last 4 weeks
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
- Exclusion Criteria - asthmatics
- Chest infection that required treatment with antibiotics within the last 4 weeks
- Patients with significant co-morbidities as judged by the investigator
- Subjects who have received research medication within the previous one month
- Subjects unable to give informed consent
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00655694
Start Date
January 1 2005
End Date
September 1 2007
Last Update
July 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart and Lung Institute
London, United Kingdom, SW3 6LY